1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Pulmonary Inflammation - Pipeline Review, H1 2014

Pulmonary Inflammation - Pipeline Review, H1 2014

  • May 2014
  • -
  • Global Markets Direct
  • -
  • 54 pages

Pulmonary Inflammation - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Pulmonary Inflammation - Pipeline Review, H1 2014’, provides an overview of the Pulmonary Inflammation’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pulmonary Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Inflammation and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pulmonary Inflammation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pulmonary Inflammation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pulmonary Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pulmonary Inflammation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Inflammation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pulmonary Inflammation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Pulmonary Inflammation - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Pulmonary Inflammation Overview 7
Therapeutics Development 8
Pipeline Products for Pulmonary Inflammation - Overview 8
Pipeline Products for Pulmonary Inflammation - Comparative Analysis 9
Pulmonary Inflammation - Therapeutics under Development by Companies 10
Pulmonary Inflammation - Therapeutics under Investigation by Universities/Institutes 12
Pulmonary Inflammation - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Pulmonary Inflammation - Products under Development by Companies 15
Pulmonary Inflammation - Products under Investigation by Universities/Institutes 16
Pulmonary Inflammation - Companies Involved in Therapeutics Development 17
Idera Pharmaceuticals, Inc. 17
Pharmaxis Limited 18
InDex Pharmaceuticals AB 19
Resolvyx Pharmaceuticals, Inc 20
Asmacure Ltee 21
Celtaxsys, Inc. 22
Pulmonary Inflammation - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
CTX-4430 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
IMO-3100 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
DIMS-9054 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
RX-20001 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
P-7 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
PXS-4728-A - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
P-16 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Drug for Radiation Pneumonitis and Radiation Induced Lung Injury - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
CpG Oligonucleotides - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
ASM-002 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
ASM-003 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
ASM-004 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
ASM-005 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
PXS-4681-A - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Second Generation LTA4H Inhibitor - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Pulmonary Inflammation - Recent Pipeline Updates 49
Pulmonary Inflammation - Dormant Projects 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

List of Tables

Number of Products under Development for Pulmonary Inflammation, H1 2014 8
Number of Products under Development for Pulmonary Inflammation - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Products under Investigation by Universities/Institutes, H1 2014 16
Pulmonary Inflammation - Pipeline by Idera Pharmaceuticals, Inc., H1 2014 17
Pulmonary Inflammation - Pipeline by Pharmaxis Limited, H1 2014 18
Pulmonary Inflammation - Pipeline by InDex Pharmaceuticals AB, H1 2014 19
Pulmonary Inflammation - Pipeline by Resolvyx Pharmaceuticals, Inc, H1 2014 20
Pulmonary Inflammation - Pipeline by Asmacure Ltee, H1 2014 21
Pulmonary Inflammation - Pipeline by Celtaxsys, Inc., H1 2014 22
Assessment by Monotherapy Products, H1 2014 23
Number of Products by Stage and Target, H1 2014 25
Number of Products by Stage and Mechanism of Action, H1 2014 27
Number of Products by Stage and Route of Administration, H1 2014 29
Number of Products by Stage and Molecule Type, H1 2014 31
Pulmonary Inflammation Therapeutics - Recent Pipeline Updates, H1 2014 49
Pulmonary Inflammation - Dormant Projects, H1 2014 52

List of Figures

Number of Products under Development for Pulmonary Inflammation, H1 2014 8
Number of Products under Development for Pulmonary Inflammation - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 23
Number of Products by Top 10 Target, H1 2014 24
Number of Products by Stage and Top 10 Target, H1 2014 25
Number of Products by Top 10 Mechanism of Action, H1 2014 26
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 27
Number of Products by Top 10 Route of Administration, H1 2014 28
Number of Products by Stage and Top 10 Route of Administration, H1 2014 29
Number of Products by Top 10 Molecule Type, H1 2014 30
Number of Products by Stage and Top 10 Molecule Type, H1 2014 31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Cancer Immunotherapy Market by Type, Application, End User - Global Forecast to 2021

Cancer Immunotherapy Market by Type, Application, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global cancer immunotherapy market is expected to reach USD 119.39 billion by 2021 from USD 61.97 billion in 2016, at a CAGR of 14.0% from 2016 to 2021. Factors such as increasing incidence of cancer, ...


Download Unlimited Documents from Trusted Public Sources

Public Health Markets in the UK

  • December 2016
    45 pages
  • Public Health  

    Obesity  

    Food  

  • United Kingdom  

    Europe  

View report >

Blood Disease Statistics in the US

  • December 2016
    11 pages
  • Blood Disease  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Related Market Segments :

Pharmaceutical
Therapy

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.